Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2024-02-29 Report Publication Anno…
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a virtual conference scheduled for March 4, 2024, to discuss the status and outlook of several key topics (masitinib approval, partnership strategy, clinical development programs, IP). This announcement is a communication intended to inform investors and the public about an upcoming event where business and pipeline updates will be discussed. This format strongly aligns with an Earnings Release (ER) if it were summarizing results, but since it is announcing a future event to discuss strategy and pipeline status, it is most closely related to an Investor Presentation (IP) or a general update. However, the core function here is announcing a call where management will discuss performance and outlook, which is often the context for an Earnings Release (ER) or a Call Transcript (CT) if the transcript were provided. Since this is the *announcement* of the call, and the content focuses on pipeline and strategy updates rather than just financial figures, it functions as a high-level update. Given the options, an announcement of a call to discuss strategy and pipeline status is often categorized alongside Earnings Releases (ER) or Investor Presentations (IP). Since it is a press release announcing a conference call to discuss status and perspectives, it is best classified as an Earnings Release (ER) if it were summarizing results, or potentially a Call Transcript (CT) if the transcript were present. As it is an announcement of a future call, and not the transcript itself, and it covers key business updates, it fits best as an ER or IP. Given the focus on 'status and perspectives' which often accompanies financial reporting, ER is a strong candidate, but since it is explicitly announcing a conference call, and not providing the results themselves, it is often a precursor to an ER or CT. If the call were an earnings call, this announcement would precede it. Since the content is a high-level update on strategy and pipeline, and it's a press release, it functions similarly to an ER announcing the discussion of results/outlook. However, if we strictly follow the definitions, it is an announcement of a future event. If the call itself were about earnings, it would be an ER. Since it's a general status update call, and not a formal financial report, it is closest to an ER (initial announcement of results/outlook) or IP. Given the structure of announcing a call followed by Q&A, it is most analogous to the event that generates a Call Transcript (CT). Since this is the announcement *of* the call, and not the transcript, and it's a press release, it is a general corporate communication. In many databases, announcements of calls that discuss strategy/pipeline are often grouped with ERs or IP. I will classify it as an ER as it serves as the initial communication regarding a period's performance/outlook discussion, even if it's a future event. Revisiting the definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is an announcement of a *conference* to discuss status. CT is 'Full text transcript of company conference calls'. Since this is a press release announcing the call, it is not the transcript. IP is 'Detailed presentation for investors'. This is an announcement, not the presentation itself. Given the nature of the announcement (status and perspectives), it is a general corporate update. Since it doesn't fit perfectly, RNS (Regulatory Filings - fallback) is possible, but ER is often used for announcements related to results discussions. Given the content focuses on pipeline and strategy updates, it is a corporate update. I will lean towards ER as it is the standard vehicle for announcing management discussions about performance/outlook, even if the discussion is future-dated.
2024-02-29 French
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
Regulatory Filings Classification · 1% confidence The document is a short press release announcing that AB Science will host a live webcast on March 4, 2024, to discuss the status and perspective on several key topics (ALS approval, partnership strategy, clinical development programs, IP). The content focuses on scheduling an event where detailed information will be shared, followed by a Q&A session. This structure—announcing a future event where detailed operational/strategic updates will be given—is characteristic of an event designed for investors or analysts, often preceding or following a major disclosure. Since it is an announcement about an upcoming event involving discussion and Q&A, it most closely aligns with the context of a conference call or investor briefing. Given the options, 'Call Transcript' (CT) is the closest fit for the *type* of discussion being announced, even though this document is the *announcement* of the call, not the transcript itself. However, applying the 'MENU VS MEAL' rule: this is an announcement about a future event, not the detailed report itself. It is not a standard regulatory filing (10-K, IR, ER). It is an announcement of a future discussion/call. If the document were the transcript, it would be CT. Since it is the announcement of the call, it functions as a general corporate update. Given the options, and recognizing it's an announcement about a future investor/analyst discussion, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if the webcast is structured like one. Since it explicitly mentions a 'live webcast' followed by Q&A, it strongly suggests an earnings/update call format. As it is only the announcement, RNS is the safest fallback, but CT represents the nature of the event being promoted. Given the focus on providing status and perspective on key business items, it is a corporate communication event. I will classify it as RNS as it is a general announcement about a future event, not the transcript (CT) or a formal presentation (IP).
2024-02-29 English
AB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLA
Legal Proceedings Report Classification · 1% confidence The document is a press release from AB Science dated February 26, 2024, announcing that Health Canada issued a Notice of Non-Compliance-Withdrawal (ANC-R) for Masitinib in ALS treatment. The company explicitly states its intention to file for a review ('demande de réexamen'). This document details the regulatory setback, the grounds for the decision, and the company's planned counter-arguments for the review process. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is a specific announcement regarding regulatory interaction and potential legal/procedural steps concerning a drug application. While it relates to regulatory matters, the core content is a detailed explanation of the regulatory decision and the company's response strategy, which aligns closely with an announcement about legal/regulatory proceedings or a specific regulatory update that doesn't fit the standard filing types. Given the focus on a specific regulatory decision (ANC-R) and the intent to challenge it, it is best classified as a Legal/Regulatory Update. However, among the provided codes, 'LTR' (Legal Proceedings Report) or 'RNS' (Regulatory Filings - fallback) are the closest. Since this is a specific regulatory action/dispute rather than a general legal proceeding (lawsuit), and it is a formal announcement, 'RNS' (Regulatory Filings) serves as the most appropriate general category for significant, non-standard regulatory communications that aren't financial reports or management changes. Given the context of a specific regulatory decision and the company's response, it is a significant regulatory announcement.
2024-02-26 French
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
Regulatory Filings Classification · 1% confidence The document is a press release dated February 26, 2024, announcing that Health Canada issued a Notice of Non-Compliance-Withdrawal (NON/w) for AB Science's drug masitinib for ALS treatment. The company explicitly states its intention to submit a Request for Reconsideration and details the arguments supporting their case against the regulatory decision. This type of communication, detailing a specific regulatory interaction, legal/procedural challenge, or significant adverse event related to drug approval/denial, fits best under the category of Legal Proceedings Report (LTR) or potentially Regulatory Filings (RNS) if LTR is too narrow. Given the focus on challenging a regulatory decision and the detailed arguments mirroring a legal/procedural defense, LTR is the most specific fit, as it covers updates on significant regulatory actions or legal matters involving the company. It is not an earnings release (ER), an interim report (IR), or a general announcement of a report (RPA).
2024-02-26 English
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
Legal Proceedings Report Classification · 1% confidence The document is a press release dated January 26, 2024, announcing an update regarding the Marketing Authorization Application (MAA) for masitinib with the European Medicines Agency (EMA). It details procedural steps (CHMP proposing written response instead of Oral Explanation) and provides an expected timeline for a decision (Q2 2024). This content relates to regulatory progress and legal/procedural matters concerning a drug application. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a general regulatory filing (RNS). Since it specifically concerns a significant legal/regulatory process update involving a drug application, it best fits the 'Legal Proceedings Report' (LTR) category, which covers significant lawsuits, regulatory actions, or legal matters. Given the context of drug approval processes being a critical regulatory/legal hurdle, LTR is the most appropriate fit among the specific options, although it is not strictly a 'lawsuit'. If LTR is interpreted narrowly, 'RNS' (Regulatory Filings - fallback) would be the next best option, but LTR captures the nature of the announcement better than a generic RNS.
2024-01-26 English
AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des Médicaments
Regulatory Filings Classification · 1% confidence The document is a press release dated January 26, 2024, providing an update on the Marketing Authorization Application (MAA) for Masitinib with the European Medicines Agency (EMA). It details procedural steps (CHMP's request for written response instead of Oral Explanation) and sets an expectation for the final opinion in Q2 2024. This type of communication, which updates stakeholders on regulatory progress, legal matters, or significant operational milestones outside of standard financial reporting (10-K, IR, ER), fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if the focus was purely on litigation, but here it is a regulatory update. Since it is an announcement about a regulatory process update and not a formal financial report, LTR is less appropriate than RNS, which serves as a general regulatory announcement fallback. Given the content is a specific, non-financial regulatory update, RNS is the most suitable classification.
2024-01-26 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.